title: [Clinical and laboratory studies with typhoid fever 178 patients].
abstract: One hundred and seventy-eight cases of typhoid patients were studied on clinical and bacteriological aspects. The main clinical findings were as follows: (1) Most of the cases had sustained fever (66.3%). (2) Gastroenterial symptoms developed as the disesase progressed. (3) Rose spots were found in 32.6% of them. (4) Liver and spleen were enlarged in 69.5% of the cases. (5) Blood eosinophil disappeared in most of the patients and leukopenia was noted in 94.3%. (6) There were toxic hepatitis (47.1%), toxic myocarditis (22.4%) and intestinal hemorrhage (19.7%) as complications. In the drug sensitivity test, the number of ampicillin-resistant and chloramphenicol-resistant strains of salmonella typhi was increased more than that seen 5 years ago (P < 0.05), however 100% of the strains were sensitive to amikacin, tobramycin, norflexacin, oflexacin and the third generation of the cephalosporin. For the time being, norflexacin and oflexacin were good and suitable drugs for the treatment of typhoid fever.
authors.affiliation: Department of Infectious Disease, Xiangya Hospital, Hunan Medical University, Changsha.
authors.forename: M
authors.initials: M
authors.lastname: Lu
authors.forename: B
authors.initials: B
authors.lastname: Ji
authors.forename: K
authors.initials: K
authors.lastname: Ouyang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006505:Hepatitis / Q000209:etiology; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009205:Myocarditis / Q000209:etiology; D009643:Norfloxacin / Q000494:pharmacology / Q000627:therapeutic use*; D015242:Ofloxacin / Q000494:pharmacology / Q000627:therapeutic use*; D012485:Salmonella typhi / Q000187:drug effects; D014435:Typhoid Fever / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000890:Anti-Infective Agents; D015242:Ofloxacin; D009643:Norfloxacin